Astrazeneca Plc (AZN) 27.60 $AZN
AstraZeneca Presents Findings from Two Pooled Analyses at the 76th Scientific Sessions of the American Diabetes Association Evaluating Dapagliflozin in Type 2 Diabetes Patients with Renal Impairment and in Combination with Potassium-Sparing Agents
BusinessWire - Sat Jun 11, 10:00AM CDT
--When co-administered with a potassium-sparing agent, FARXIGA reduced A1C, body weight and systolic blood pressure without significantly increasing potassium levels
AZN: 27.60 (-0.37)
AstraZeneca Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes
BusinessWire - Sat Jun 11, 10:00AM CDT
--Additional poster further explores the impact of BYDUREON on 24-hour glucose patterns in patients with type 2 diabetes
AZN: 27.60 (-0.37)
Ironwood/Allergan's Linzess sNDA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 10:31AM CDT
Ironwood (IRWD) and Allergan's (AGN) sNDA for the 72 mcg dose of Linzess for the treatment of adults with CIC has been accepted for review by the FDA.
AGN: 243.55 (+2.62), IRWD: 12.75 (-0.12), AZN: 27.60 (-0.37), JNP: 7.04 (+0.13)
Valeant To Participate In FDA Advisory Committee Meeting On July 19
PR Newswire - Thu Jun 09, 4:40PM CDT
Committee to Review Valeant's BLA 761032 Brodalumab Subcutaneous Injection For Treatment of Adult Patients with Moderate to Severe Plaque Psoriasis
VRX: 23.78 (-0.36), AZN: 27.60 (-0.37), VRX.TO: 30.52 (-0.28)
AstraZeneca Falls 2.38% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jun 09, 2:30PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.92 to a high of $29.37. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $29.60 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 27.60 (-0.37)
Look for Shares of AstraZeneca to Potentially Rebound after Yesterday's 2.38% Sell Off
Comtex SmarTrend(R) - Thu Jun 09, 2:28PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.92 to a high of $29.37. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $29.60 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 27.60 (-0.37)
AstraZeneca to Highlight Scientific Advancements Across Its Diabetes Portfolio at the American Diabetes Association 76th Scientific Sessions
BusinessWire - Wed Jun 08, 7:00AM CDT
--21 abstracts on dapagliflozin, including an investigation of its effects on cardiovascular risk factors in type 2 diabetes with varying degrees of renal function and insights on its use in a real-world setting
AZN: 27.60 (-0.37)
AstraZeneca Presents Tagrisso Leptomeningeal Disease Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 10:51AM CDT
AstraZeneca (AZN) presented clinical and safety data from a phase I study (BLOOM) on Tagrisso in patients with leptomeningeal disease at ASCO.
ANIP: 53.19 (+1.14), AZN: 27.60 (-0.37), RTRX: 17.19 (-0.21), BMY: 72.22 (-0.43)
Tagrisso (Osimertinib) Shows Clinical Activity in Patients with Leptomeningeal Disease from Lung Cancer
BusinessWire - Mon Jun 06, 11:38AM CDT
--Latest results reinforce pre-clinical evidence that osimertinib crosses the blood-brain barrier
AZN: 27.60 (-0.37)
Puma (PBYI) Presents Favorable Phase II Data on Neratinib
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:33AM CDT
Puma Biotechnology (PBYI) presented positive data from a phase II study on neratinib in patients with HER2-mutated, non-amplified breast cancer at ASCO.
ANIP: 53.19 (+1.14), AZN: 27.60 (-0.37), RTRX: 17.19 (-0.21), PBYI: 32.92 (-0.49)
LYNPARZA (olaparib): Latest Data Suggest Potential Overall Survival Advantage in Patients with Platinum Sensitive Ovarian Cancer
BusinessWire - Sun Jun 05, 10:50AM CDT
AstraZeneca today presented results from a third interim analysis of Study 19 that suggest an improvement in overall survival (OS) for patients with ovarian cancer treated with olaparib maintenance therapy following platinum-based chemotherapy. This was a secondary endpoint of the trial. These results support the previously reported benefits of olaparib in progression-free survival (PFS) compared to placebo, the primary endpoint of the trial.
AZN: 27.60 (-0.37)
Durvalumab Monotherapy Demonstrates Efficacy in Urothelial Bladder Cancer
BusinessWire - Sun Jun 05, 9:42AM CDT
--PD-L1 expression correlates with response to durvalumab monotherapy per Ventana SP263 assay(1)
AZN: 27.60 (-0.37)
AstraZeneca Sells Zurampic's EU and Latin American Rights
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 9:19AM CDT
AstraZeneca (AZN) entered into a licensing agreement granting Gr??nenthal the rights to its gout drug Zurampic in the EU and Latin America.
IRWD: 12.75 (-0.12), ANIP: 53.19 (+1.14), AZN: 27.60 (-0.37), BMY: 72.22 (-0.43)
SeeThruEquity Issues Company Update on TapImmune Highlighting New Phase 2 Clinical Study with AstraZeneca to Begin at Memorial Sloan Kettering
ACCESSWIRE - Thu Jun 02, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / June 2, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on TapImmune Inc. (OTCQB: TPIV).
AZN: 27.60 (-0.37)
AstraZeneca Reports Positive Phase III Data on Faslodex
Zacks Equity Research - Zacks Investment Research - Tue May 31, 8:03AM CDT
AstraZeneca (AZN) announced positive data from a phase III FALCON study on Faslodex for the treatment of advanced breast cancer.
ANIP: 53.19 (+1.14), PFE: 34.74 (-0.55), AZN: 27.60 (-0.37), BMY: 72.22 (-0.43)
Allergan Receives FDA Approval of TEFLARO® (ceftaroline fosamil) for Pediatric Patients
PR Newswire - Tue May 31, 6:31AM CDT
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) for TEFLARO® (ceftaroline fosamil), granting new indications for pediatric patients 2 months of age to less than 18 years of age with acute bacterial skin and skin structure infections (ABSSSI), including infections caused by methicillin-resistant Staphylococcus aureus (MRSA), and community-acquired bacterial pneumonia (CABP) caused by Streptococcus pneumoniae and other designated susceptible bacteria.
AGN: 243.55 (+2.62), AZN: 27.60 (-0.37)
Relypsa (RLYP) Shows Strength: Stock Moves 8.8% Higher
Zacks Equity Research - Zacks Investment Research - Mon May 30, 7:15AM CDT
Relypsa, Inc. (RLYP) shares rose almost 9% in the last trading session.
RLYP: 19.75 (+0.41), AZN: 27.60 (-0.37)
Relypsa Up on CRL for AstraZeneca Hyperkalemia Drug
Zacks Equity Research - Zacks Investment Research - Mon May 30, 6:30AM CDT
Shares of Relypsa, Inc. (RLYP) gained after AstraZeneca (AZN) received a CRL regarding its NDA for its hyperkalemia candidate, ZS-9.
RLYP: 19.75 (+0.41), PFE: 34.74 (-0.55), AZN: 27.60 (-0.37), BMY: 72.22 (-0.43)
AstraZeneca's Fulvestrant Met Its Primary Endpoint as First-Line Treatment in a Phase III Trial for HR+ Advanced Breast Cancer
BusinessWire - Fri May 27, 6:00AM CDT
AstraZeneca today announced positive results from the Phase III FALCON trial comparing fulvestrant 500mg to anastrozole 1mg for the treatment of locally-advanced or metastatic breast cancer, in postmenopausal women who have not had prior hormonal treatment for hormone receptor positive (HR+) breast cancer.(1)
AZN: 27.60 (-0.37)
AstraZeneca Set to Possibly Pullback After Yesterday's Rally of 1.70%
Comtex SmarTrend(R) - Wed May 25, 2:28PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $29.76 to a high of $30.00. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $29.53 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 27.60 (-0.37)
AstraZeneca Presents Findings from Two Pooled Analyses at the 76th Scientific Sessions of the American Diabetes Association Evaluating Dapagliflozin in Type 2 Diabetes Patients with Renal Impairment and in Combination with Potassium-Sparing Agents
BusinessWire - Sat Jun 11, 10:00AM CDT
--When co-administered with a potassium-sparing agent, FARXIGA reduced A1C, body weight and systolic blood pressure without significantly increasing potassium levels
AZN: 27.60 (-0.37)
AstraZeneca Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes
BusinessWire - Sat Jun 11, 10:00AM CDT
--Additional poster further explores the impact of BYDUREON on 24-hour glucose patterns in patients with type 2 diabetes
AZN: 27.60 (-0.37)
Ironwood/Allergan's Linzess sNDA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 10:31AM CDT
Ironwood (IRWD) and Allergan's (AGN) sNDA for the 72 mcg dose of Linzess for the treatment of adults with CIC has been accepted for review by the FDA.
AGN: 243.55 (+2.62), IRWD: 12.75 (-0.12), AZN: 27.60 (-0.37), JNP: 7.04 (+0.13)
Valeant To Participate In FDA Advisory Committee Meeting On July 19
PR Newswire - Thu Jun 09, 4:40PM CDT
Committee to Review Valeant's BLA 761032 Brodalumab Subcutaneous Injection For Treatment of Adult Patients with Moderate to Severe Plaque Psoriasis
VRX: 23.78 (-0.36), AZN: 27.60 (-0.37), VRX.TO: 30.52 (-0.28)
AstraZeneca Falls 2.38% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jun 09, 2:30PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.92 to a high of $29.37. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $29.60 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 27.60 (-0.37)
Look for Shares of AstraZeneca to Potentially Rebound after Yesterday's 2.38% Sell Off
Comtex SmarTrend(R) - Thu Jun 09, 2:28PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $28.92 to a high of $29.37. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $29.60 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 27.60 (-0.37)
AstraZeneca to Highlight Scientific Advancements Across Its Diabetes Portfolio at the American Diabetes Association 76th Scientific Sessions
BusinessWire - Wed Jun 08, 7:00AM CDT
--21 abstracts on dapagliflozin, including an investigation of its effects on cardiovascular risk factors in type 2 diabetes with varying degrees of renal function and insights on its use in a real-world setting
AZN: 27.60 (-0.37)
AstraZeneca Presents Tagrisso Leptomeningeal Disease Data
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 10:51AM CDT
AstraZeneca (AZN) presented clinical and safety data from a phase I study (BLOOM) on Tagrisso in patients with leptomeningeal disease at ASCO.
ANIP: 53.19 (+1.14), AZN: 27.60 (-0.37), RTRX: 17.19 (-0.21), BMY: 72.22 (-0.43)
Tagrisso (Osimertinib) Shows Clinical Activity in Patients with Leptomeningeal Disease from Lung Cancer
BusinessWire - Mon Jun 06, 11:38AM CDT
--Latest results reinforce pre-clinical evidence that osimertinib crosses the blood-brain barrier
AZN: 27.60 (-0.37)
Puma (PBYI) Presents Favorable Phase II Data on Neratinib
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:33AM CDT
Puma Biotechnology (PBYI) presented positive data from a phase II study on neratinib in patients with HER2-mutated, non-amplified breast cancer at ASCO.
ANIP: 53.19 (+1.14), AZN: 27.60 (-0.37), RTRX: 17.19 (-0.21), PBYI: 32.92 (-0.49)
LYNPARZA (olaparib): Latest Data Suggest Potential Overall Survival Advantage in Patients with Platinum Sensitive Ovarian Cancer
BusinessWire - Sun Jun 05, 10:50AM CDT
AstraZeneca today presented results from a third interim analysis of Study 19 that suggest an improvement in overall survival (OS) for patients with ovarian cancer treated with olaparib maintenance therapy following platinum-based chemotherapy. This was a secondary endpoint of the trial. These results support the previously reported benefits of olaparib in progression-free survival (PFS) compared to placebo, the primary endpoint of the trial.
AZN: 27.60 (-0.37)
Durvalumab Monotherapy Demonstrates Efficacy in Urothelial Bladder Cancer
BusinessWire - Sun Jun 05, 9:42AM CDT
--PD-L1 expression correlates with response to durvalumab monotherapy per Ventana SP263 assay(1)
AZN: 27.60 (-0.37)
AstraZeneca Sells Zurampic's EU and Latin American Rights
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 9:19AM CDT
AstraZeneca (AZN) entered into a licensing agreement granting Gr??nenthal the rights to its gout drug Zurampic in the EU and Latin America.
IRWD: 12.75 (-0.12), ANIP: 53.19 (+1.14), AZN: 27.60 (-0.37), BMY: 72.22 (-0.43)
SeeThruEquity Issues Company Update on TapImmune Highlighting New Phase 2 Clinical Study with AstraZeneca to Begin at Memorial Sloan Kettering
ACCESSWIRE - Thu Jun 02, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / June 2, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on TapImmune Inc. (OTCQB: TPIV).
AZN: 27.60 (-0.37)
AstraZeneca Reports Positive Phase III Data on Faslodex
Zacks Equity Research - Zacks Investment Research - Tue May 31, 8:03AM CDT
AstraZeneca (AZN) announced positive data from a phase III FALCON study on Faslodex for the treatment of advanced breast cancer.
ANIP: 53.19 (+1.14), PFE: 34.74 (-0.55), AZN: 27.60 (-0.37), BMY: 72.22 (-0.43)
Allergan Receives FDA Approval of TEFLARO® (ceftaroline fosamil) for Pediatric Patients
PR Newswire - Tue May 31, 6:31AM CDT
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) for TEFLARO® (ceftaroline fosamil), granting new indications for pediatric patients 2 months of age to less than 18 years of age with acute bacterial skin and skin structure infections (ABSSSI), including infections caused by methicillin-resistant Staphylococcus aureus (MRSA), and community-acquired bacterial pneumonia (CABP) caused by Streptococcus pneumoniae and other designated susceptible bacteria.
AGN: 243.55 (+2.62), AZN: 27.60 (-0.37)
Relypsa (RLYP) Shows Strength: Stock Moves 8.8% Higher
Zacks Equity Research - Zacks Investment Research - Mon May 30, 7:15AM CDT
Relypsa, Inc. (RLYP) shares rose almost 9% in the last trading session.
RLYP: 19.75 (+0.41), AZN: 27.60 (-0.37)
Relypsa Up on CRL for AstraZeneca Hyperkalemia Drug
Zacks Equity Research - Zacks Investment Research - Mon May 30, 6:30AM CDT
Shares of Relypsa, Inc. (RLYP) gained after AstraZeneca (AZN) received a CRL regarding its NDA for its hyperkalemia candidate, ZS-9.
RLYP: 19.75 (+0.41), PFE: 34.74 (-0.55), AZN: 27.60 (-0.37), BMY: 72.22 (-0.43)
AstraZeneca's Fulvestrant Met Its Primary Endpoint as First-Line Treatment in a Phase III Trial for HR+ Advanced Breast Cancer
BusinessWire - Fri May 27, 6:00AM CDT
AstraZeneca today announced positive results from the Phase III FALCON trial comparing fulvestrant 500mg to anastrozole 1mg for the treatment of locally-advanced or metastatic breast cancer, in postmenopausal women who have not had prior hormonal treatment for hormone receptor positive (HR+) breast cancer.(1)
AZN: 27.60 (-0.37)
AstraZeneca Set to Possibly Pullback After Yesterday's Rally of 1.70%
Comtex SmarTrend(R) - Wed May 25, 2:28PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $29.76 to a high of $30.00. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $29.53 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 27.60 (-0.37)
